MindMed, a biomedical company that develops psychedelic-based products for brain disorders, secured $50 million
The company says it will help them in areas such as their Phase 2b study of MM-120 (their optimized form of LSD) for the treatment of generalized anxiety disorder later this year.
Read the article on Business Wire >
Read More from the Global Wellness News ™